샘플 요청 목록

 카트 문의
시장보고서
상품코드
1793031

세계의 전이성 대장암 치료제 시장

Metastatic Colorectal Cancer Drugs
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 279 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 전이성 대장암 치료제 시장은 2030년까지 38억 달러에 이를 전망

2024년에 33억 달러로 추정된 전이성 대장암 치료제 세계 시장은 2024-2030년의 분석 기간에 CAGR 2.6%로 성장하여 2030년에는 38억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 항EGFR 억제제는 CAGR 2.2%를 나타내고, 분석 기간 종료시에는 18억 달러에 이를 것으로 예측됩니다. 항VEGF 치료제 부문의 성장률은 분석 기간중 CAGR 1.9%로 추정됩니다.

미국 시장은 8억 9,870만 달러로 추정, 중국은 CAGR 4.9%를 보일 것으로 예측

미국의 전이성 대장암 치료제 시장은 2024년에 8억 9,870만 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 7억 3,870만 달러 규모에 이를 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 4.9%로 추정됩니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 1.0%와 2.0%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 1.4%를 나타낼 전망입니다.

세계의 전이성 대장암 치료제 시장 - 주요 동향과 촉진요인 정리

기술 혁신은 전이성 대장암 치료를 어떻게 재구성하고 있는가?

전이성 대장암(mCRC)의 치료 환경은 과학적 혁신과 보다 개인화된 치료 접근법의 등장으로 큰 변화의 시기를 맞이하고 있습니다. FOLFOX나 FOLFIRI와 같은 전통적인 화학요법은 여전히 mCRC 치료의 근간을 이루고 있지만, 표적치료제나 면역요법으로 보강되거나 대체되는 경우가 늘고 있습니다. 세툭시맙이나 파니툼맙과 같은 상피세포성장인자수용체(EGFR) 억제제나 베바시주맙과 같은 혈관내피성장인자(VEGF) 억제제와 같은 특정 바이오마커를 표적으로 하는 약물은 종양 프로파일에 따라 환자에게 더 적합한 치료법을 도입하고 있습니다. 유전체 프로파일링과 액체생검 기술의 발전으로 종양 전문의는 KRAS, NRAS, BRAF 등의 돌연변이를 식별할 수 있게 되었으며, 이는 치료법 선택에 중요한 역할을 하고 있습니다. 펨브롤리주맙, 니볼루맙과 같은 면역관문억제제는 마이크로새틀라이트 불안정성이 높은(MSI-H) 또는 불일치수복결손(dMMR) 종양 환자에서 화학요법만으로는 볼 수 없는 지속적인 반응을 보이며 놀라운 성과를 보이고 있습니다. 또한, 이중 특이성 항체나 항체-약물 복합체는 보다 특이성이 높은 세포독성 약물을 암세포에 직접 전달할 수 있는 유망한 치료법으로 떠오르고 있습니다. 정밀의료가 강조되면서 HER2 증폭형, NTRK 융합형 양성 mCRC 등 희귀한 아형에 맞춘 저분자 억제제 개발도 진행되고 있습니다. 또한, 내성을 극복하고 생존기간을 연장하기 위해 여러 작용기전을 포함하는 병용요법이 적극적으로 검토되고 있습니다. 이러한 기술 혁신으로 전이성 결장직장암 치료는 획일적인 모델에서 보다 개별화되고 효과적인 치료로 패러다임이 전환되고 있습니다.

임상시험과 바이오마커 탐색이 미래의 파이프라인을 어떻게 형성할 것인가?

세계 전이성 대장암 치료제 파이프라인은 새로운 치료제뿐만 아니라 새로운 예측 및 예후 바이오마커 발굴에 초점을 맞춘 임상 연구 활동의 급증으로 인해 큰 영향을 받고 있습니다. 임상 1상부터 3상까지의 임상시험은 바이오마커에 의한 계층화를 염두에 두고 설계되어 다양한 유전자 프로파일에 대한 치료 효과를 보다 정확하게 평가할 수 있게 되었습니다. 연구 개발자들은 KRAS G12C, PI3K, MET 등의 새로운 표적을 조사했으며, 동시에 기존 약제 내성을 극복할 수 있는 차세대 억제제를 개발하고 있습니다. 액체 생검과 순환 종양 DNA(ctDNA) 기술은 미세 잔존 병변의 식별, 치료 효과 모니터링, 재발의 조기 발견에 있어 점점 더 큰 역할을 하고 있습니다. 이러한 발전은 새로운 데이터에 따라 수정이 가능한 적응형 임상시험 설계로의 전환을 가속화하여 유망한 신약 후보물질 시장 출시 시간을 단축하고 있습니다. 또한, 학계, 제약사, 규제 당국 간의 협력으로 연구 일정을 앞당기고 임상시험용 의약품에 대한 접근성을 확대하고 있습니다. 또한, 체크포인트 억제제, 암 백신, T세포 요법을 포함한 면역요법의 조합은 무진행 생존율과 전체 생존율의 개선을 기대할 수 있어 진행 단계에서 엄격하게 시험되고 있습니다. 특정 치료법에 특별히 잘 반응하는 하위 그룹을 식별하는 시험의 성공은 치료 라인의 재정의와 유지 전략의 개발을 촉진하고 있습니다. 신약 개발 기업들이 실제 증거와 국제 임상시험 데이터를 기반으로 개발을 지속함에 따라, mCRC 파이프라인은 더욱 다양해지고, 계층화되고, 진화하는 질병에 대한 분자적 이해에 부합하는 방향으로 발전하고 있습니다.

어떤 시장 역학이 약물의 접근성과 채택에 영향을 미치고 있는가?

전이성 대장암 치료제의 접근성과 채택은 지역마다 크게 다른 규제, 경제, 의료 시스템의 역학관계의 복잡한 상호작용의 영향을 받습니다. 고소득 국가에서는 강력한 상환 체계, 신속한 규제 당국의 승인, 정밀 진단에 대한 광범위한 접근으로 첨단 치료법을 쉽게 이용할 수 있습니다. 그러나 중저소득 지역에서는 비용 장벽, 제한된 의료 인프라, 불충분한 검진 프로그램 등으로 인해 의약품에 대한 접근성이 여전히 제한되고 있습니다. 생물학적 제제 및 면역치료제의 높은 가격은 신흥국 시장에서도 여전히 큰 이슈가 되고 있으며, 가치 기반 가격 책정 모델과 결과 기반 상환 계약에 대한 관심이 높아지고 있습니다. VEGF 억제제와 EGFR 억제제의 경우 바이오시밀러가 시장에 출시되기 시작했으며, 비용 절감과 생물학적 제제에 대한 접근성 확대 가능성이 있습니다. 또한, 의료 서비스 제공업체와 보험사들은 비용 효율적이고 근거에 기반한 치료법을 지지하는 임상 경로와 치료 가이드라인을 채택하고 있으며, 이는 처방 행태에 영향을 미치고 있습니다. 환자 지원 단체와 비정부기구도 인식 제고, 접근성 프로그램 자금 지원, 정책 변화 옹호 등 보다 적극적인 역할을 하고 있습니다. 원격 종양학 플랫폼, 분자진단 도구와 통합된 전자 의료 기록과 같은 디지털 건강 도구는 적시에 진단하고 개인화된 치료 계획을 세우는 데 도움을 주고 있습니다. 한편, 유전체 검사에 대한 접근성 격차는 여전히 병목 현상으로 많은 환경에서 정밀의료의 실제 적용을 제한하고 있습니다. 전 세계 의료 시스템이 복잡한 암 치료에 적응해 나가면서 비용, 접근성, 임상 효과의 역학은 mCRC 치료제의 채택과 유통을 관리하는 의사결정 과정에서 점점 더 핵심적인 요소로 자리 잡고 있습니다.

전이성 대장암 치료제 시장의 성장을 가속하는 요인은 무엇인가?

전이성 대장암 치료제 시장의 성장은 진화하는 치료 기술, 발병률 증가, 정밀 종양학에 대한 전 세계의 관심 증가 등 여러 요인에 의해 주도되고 있습니다. 주요 성장 요인 중 하나는 환자 수 확대입니다. 대장암은 여전히 세계에서 가장 흔한 암 중 하나이며, 환자의 상당수가 진행기 또는 전이기에 진단되기 때문입니다. 바이오마커 탐색과 분자진단학의 발전은 보다 정확한 환자 분류를 가능하게 하고, 이를 통해 향상된 임상 결과를 나타내는 표적치료와 면역치료의 채택을 뒷받침하고 있습니다. 특정 작용기전을 가진 저분자 화합물 및 생물학적 제제를 포함한 새로운 약물의 FDA 및 EMA 승인 건수가 증가하고 있으며, 임상의가 이용할 수 있는 치료 수단이 빠르게 확대되고 있습니다. 제약회사들은 암 연구 개발 파이프라인에 많은 투자를 하고 있으며, 전이성 대장암은 미충족된 임상적 필요와 시장 잠재력 때문에 전략적 초점이 되고 있습니다. 병용요법의 통합은 치료의 복잡성과 기간을 촉진하고, 환자 1인당 시장가치를 높이고 있습니다. 또한, 동반진단 약물과 분자 프로파일링 도구에 대한 접근성이 향상됨에 따라 더 많은 계층에서 정밀치료의 실현가능성이 높아지고 있습니다. 실제 임상 데이터와 시판 후 조사의 보급은 제조업체가 장기적인 가치를 입증하고 규제 당국의 승인과 유리한 상환 결정을 뒷받침하는 데 도움이 됩니다. 또한, 학술연구센터와 바이오제약기업과의 협력 강화는 기술 혁신을 가속화하고 임상시험 참여를 확대하고 있습니다. 마지막으로, 환자 중심주의, 의료보험 적용 범위 확대, 삶의 질 지표에 대한 중요성 증가는 전 세계적으로 mCRC 치료제 시장의 지속적인 성장에 유리한 환경을 조성하고 있습니다.

부문

약제 클래스(항EGFR 억제제, 항VEGF 요법, 항HER2 요법, 면역 관문 억제제, 기타 약제 클래스별), 유통 채널(병원 약국, 소매 약국, 온라인 유통 채널)

조사 대상 기업 예

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company, Limited
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Genentech, Inc.
  • Merck & Co., Inc.
  • Merck KGaA(EMD Serono)
  • Mirati Therapeutics, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Qilu Pharmaceutical Co., Ltd.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Taiho Pharmaceutical Co., Ltd.

AI 통합

당사는 유효한 전문가 컨텐츠와 AI툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 25.08.26

Global Metastatic Colorectal Cancer Drugs Market to Reach US$3.8 Billion by 2030

The global market for Metastatic Colorectal Cancer Drugs estimated at US$3.3 Billion in the year 2024, is expected to reach US$3.8 Billion by 2030, growing at a CAGR of 2.6% over the analysis period 2024-2030. Anti-EGFR Inhibitors, one of the segments analyzed in the report, is expected to record a 2.2% CAGR and reach US$1.8 Billion by the end of the analysis period. Growth in the Anti-VEGF Therapies segment is estimated at 1.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$898.7 Million While China is Forecast to Grow at 4.9% CAGR

The Metastatic Colorectal Cancer Drugs market in the U.S. is estimated at US$898.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$738.7 Million by the year 2030 trailing a CAGR of 4.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.0% and 2.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.4% CAGR.

Global Metastatic Colorectal Cancer Drugs Market - Key Trends & Drivers Summarized

How Is Innovation Reshaping Treatment for Metastatic Colorectal Cancer?

The treatment landscape for metastatic colorectal cancer (mCRC) is undergoing a profound transformation driven by scientific innovation and the emergence of more personalized therapeutic approaches. Traditional chemotherapeutic regimens such as FOLFOX and FOLFIRI continue to form the backbone of mCRC treatment, but they are increasingly being augmented or replaced by targeted therapies and immunotherapies. Drugs targeting specific biomarkers, such as epidermal growth factor receptor (EGFR) inhibitors like cetuximab and panitumumab, and vascular endothelial growth factor (VEGF) inhibitors like bevacizumab, have introduced more tailored options for patients based on their tumor profiles. Advances in genomic profiling and liquid biopsy techniques are enabling oncologists to identify mutations such as KRAS, NRAS, and BRAF, which play a critical role in therapy selection. For patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) tumors, immune checkpoint inhibitors such as pembrolizumab and nivolumab have demonstrated remarkable outcomes, offering durable responses not seen with chemotherapy alone. Moreover, bispecific antibodies and antibody-drug conjugates are emerging as promising modalities, delivering cytotoxic agents directly to cancer cells with greater specificity. The growing emphasis on precision medicine is also leading to increased development of small-molecule inhibitors tailored to rare subtypes, including HER2-amplified or NTRK fusion-positive mCRC. Additionally, combination regimens involving multiple mechanisms of action are being actively explored to overcome resistance and extend survival. These innovations are collectively shifting the paradigm from a one-size-fits-all model to a more individualized and effective treatment landscape for metastatic colorectal cancer.

How Are Clinical Trials and Biomarker Discovery Shaping the Future Pipeline?

The global pipeline for metastatic colorectal cancer drugs is being heavily influenced by a surge in clinical research activity, focused not only on novel therapeutics but also on uncovering new predictive and prognostic biomarkers. Phase I to Phase III clinical trials are increasingly designed with biomarker stratification in mind, enabling a more precise evaluation of treatment efficacy across diverse genetic profiles. Researchers are investigating new targets such as KRAS G12C, PI3K, and MET, while simultaneously developing next-generation inhibitors that can overcome existing drug resistance. Liquid biopsy and circulating tumor DNA (ctDNA) technologies are playing a growing role in identifying minimal residual disease, monitoring therapeutic response, and enabling early detection of relapse. These advances are accelerating the move toward adaptive clinical trial designs, which allow for modifications in response to emerging data, thereby reducing time-to-market for promising drug candidates. Collaboration between academic institutions, pharmaceutical companies, and regulatory agencies is also expediting research timelines and expanding access to investigational drugs. Furthermore, immunotherapy combinations involving checkpoint inhibitors, cancer vaccines, and T-cell therapies are being rigorously tested in advanced stages of the disease, with the hope of improving progression-free and overall survival rates. The success of trials in identifying subgroups that respond exceptionally well to certain therapies is prompting a redefinition of treatment lines and the development of maintenance strategies. As drug developers continue to build on real-world evidence and global clinical trial data, the mCRC pipeline is becoming more diversified, stratified, and aligned with the evolving molecular understanding of the disease.

What Market Dynamics Are Influencing Drug Accessibility and Adoption?

The accessibility and adoption of metastatic colorectal cancer drugs are influenced by a complex interplay of regulatory, economic, and healthcare system dynamics that vary significantly by region. In high-income countries, advanced treatments are more readily available due to strong reimbursement frameworks, faster regulatory approvals, and widespread access to precision diagnostics. However, in middle- and low-income regions, drug access remains constrained by cost barriers, limited healthcare infrastructure, and inadequate screening programs. The high cost of biologics and immunotherapies continues to pose a significant challenge, even in developed markets, leading to increased focus on value-based pricing models and outcomes-based reimbursement agreements. Biosimilars are beginning to enter the market for VEGF and EGFR inhibitors, potentially reducing costs and expanding access to biologic therapies. Furthermore, healthcare providers and insurers are increasingly adopting clinical pathways and treatment guidelines that favor cost-effective yet evidence-based therapies, thereby influencing prescribing behavior. Patient advocacy groups and non-governmental organizations are also playing a more active role in promoting awareness, funding access programs, and advocating for policy changes. Digital health tools, such as tele-oncology platforms and electronic health records integrated with molecular diagnostic tools, are aiding in timely diagnosis and personalized treatment planning. Meanwhile, disparities in access to genomic testing remain a bottleneck, limiting the real-world application of precision medicine in many settings. As global health systems continue to adapt to the complexities of oncology care, the dynamics of cost, access, and clinical efficacy are increasingly central to the decision-making processes that govern mCRC drug adoption and distribution.

What Factors Are Driving Growth in the Metastatic Colorectal Cancer Drugs Market?

The growth in the metastatic colorectal cancer drugs market is driven by several factors rooted in evolving therapeutic technologies, rising incidence rates, and increasing global focus on precision oncology. One of the primary growth drivers is the expanding patient population, as colorectal cancer remains among the most common cancers worldwide and a significant portion of patients are diagnosed at an advanced or metastatic stage. Advances in biomarker discovery and molecular diagnostics are enabling more accurate patient stratification, which in turn supports the adoption of targeted therapies and immunotherapies that are showing improved clinical outcomes. The increasing number of FDA and EMA approvals for novel agents, including small molecules and biologics with specific mechanisms of action, is rapidly expanding the therapeutic arsenal available to clinicians. Pharmaceutical companies are heavily investing in oncology R&D pipelines, with metastatic colorectal cancer representing a strategic focus due to unmet clinical needs and market potential. The integration of combination therapies is driving treatment complexity and duration, thereby increasing the market value per patient. In addition, improved access to companion diagnostics and molecular profiling tools is making precision treatment more feasible across broader demographics. The proliferation of real-world data and post-marketing surveillance is helping manufacturers demonstrate long-term value, which supports regulatory acceptance and favorable reimbursement decisions. Furthermore, greater collaboration between academic research centers and biopharmaceutical firms is accelerating innovation and expanding clinical trial participation. Finally, patient-centric initiatives, expanded healthcare coverage, and a growing emphasis on quality of life metrics are shaping a more favorable environment for the sustained growth of the mCRC drugs market globally.

SCOPE OF STUDY:

The report analyzes the Metastatic Colorectal Cancer Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors, Other Drug Classes); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company, Limited
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Genentech, Inc.
  • Merck & Co., Inc.
  • Merck KGaA (EMD Serono)
  • Mirati Therapeutics, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Qilu Pharmaceutical Co., Ltd.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Taiho Pharmaceutical Co., Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Metastatic Colorectal Cancer Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Prevalence of Late-Stage Diagnoses Throws the Spotlight on Demand for Targeted mCRC Therapies
    • Advancements in Biomarker-Driven Treatment Protocols Drive Adoption of Precision Oncology Drugs
    • Expansion of Immunotherapy Indications Spurs Growth in Checkpoint Inhibitor-Based Combinations
    • Rising Uptake of Liquid Biopsy Accelerates Demand for Molecularly Targeted mCRC Therapies
    • Personalized Medicine Trends Strengthen the Business Case for Genomic-Guided Treatment Approaches
    • Development of Novel Antibody-Drug Conjugates (ADCs) Propels Innovation in Late-Line mCRC Treatment
    • High Treatment Costs and Reimbursement Challenges Create Barriers but Also Opportunities for Value-Based Drug Models
    • Growing Emphasis on Quality of Life and Extended Survival Generates Demand for Less Toxic Therapeutic Options
    • Combination Therapies with Chemotherapy and Biologics Expand the Addressable Market for Drug Developers
    • Emergence of Small Molecule Inhibitors Disrupts Traditional Biologic-Only Treatment Paradigms
    • Rising Access to Oncology Care in Emerging Markets Expands Commercial Opportunities for Global mCRC Drug Makers
    • Evolving Companion Diagnostics Ecosystem Drives Precision in Drug Selection and Treatment Outcomes for mCRC
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Metastatic Colorectal Cancer Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Metastatic Colorectal Cancer Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Anti-EGFR Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Anti-EGFR Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Anti-EGFR Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Anti-VEGF Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Anti-VEGF Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Anti-VEGF Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Anti-HER2 Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Anti-HER2 Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Anti-HER2 Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Immune Checkpoint Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Immune Checkpoint Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Immune Checkpoint Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Metastatic Colorectal Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • JAPAN
    • Metastatic Colorectal Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • CHINA
    • Metastatic Colorectal Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: China 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: China 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • EUROPE
    • Metastatic Colorectal Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Metastatic Colorectal Cancer Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • FRANCE
    • Metastatic Colorectal Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: France 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: France 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • GERMANY
    • Metastatic Colorectal Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Metastatic Colorectal Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Metastatic Colorectal Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Metastatic Colorectal Cancer Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Metastatic Colorectal Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • INDIA
    • Metastatic Colorectal Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: India 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: India 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Metastatic Colorectal Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Metastatic Colorectal Cancer Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Metastatic Colorectal Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Metastatic Colorectal Cancer Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • AFRICA
    • Metastatic Colorectal Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Metastatic Colorectal Cancer Drugs by Drug Class - Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-EGFR Inhibitors, Anti-VEGF Therapies, Anti-HER2 Therapies, Immune Checkpoint Inhibitors and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Metastatic Colorectal Cancer Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for Metastatic Colorectal Cancer Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제